Trial Profile

Phase 1 Study of the PKMYT1 Inhibitor RP-6306 in Combination With Gemcitabine for the Treatment of Advanced Solid Tumors (MAGNETIC Study)

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 18 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Gemcitabine (Primary) ; Lunresertib (Primary)
Indications Solid tumours
Focus Adverse reactions; Proof of concept
Acronyms MAGNETIC
Sponsors Repare Therapeutics

Most Recent Events

17 Jun 2025 Status changed from active, no longer recruiting to discontinued as the sponsor decided to terminate the study
28 Feb 2024 According to a Repare Therapeutics media release, enrollment in this trial is now closed.
26 Jan 2024 Planned primary completion date changed from 31 Oct 2023 to 31 Dec 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com